HYCM
30.3.2017 10:53:26 CEST | Business Wire | Press release
HYCM, an FCA-regulated global leader in online capital markets trading, has confirmed that its Cyprus-based entity HYCM Europe is licenced and regulated by the Cyprus Securities and Exchange Commission (CySEC). The status is now reflected on the company website.
CySEC is Cyprus’s financial regulator which provides a framework within which the country’s financial services companies are obliged to operate. As a CySEC regulated broker, HYCM must adhere to the strictest financial standards, including capital adequacy requirements, segregation of client funds and transparency of business operations.
An international broker with a strong presence in key markets in Asia, Middle East and the United Kingdom, HYCM is now set to expand its footprint in the European Union, providing traders with the opportunity to benefit from competitive pricing, high execution speed, high levels of financial security and its renowned customer support.
Commenting on the CySEC licence, Stavros Lambouris, CEO, HYCM Europe said, “The CySEC authorisation marks a milestone in our history as part of our plans to expand our global operations. We now have a gateway to the European market, affirming our commitment to our European clients whilst rubber-stamping the company’s position as a global leader”.
HYCM is part of the Henyep Capital Markets Group, an international conglomerate which recently rebranded its UAE operations within the DIFC to unify its offices worldwide and to reflect the broad range of capital markets products on offer to its retail clients. DFSA-regulated Henyep Investment Bank Limited became known as Henyep Capital Markets (DIFC) Ltd as part of its plans for growth in the region, particularly within the UAE.
The latest move means that European clients can now experience HYCM’s full product offering including forex, commodities and equities as well as positioning the 40 year old Group on a renewed growth path as it seeks to extend its global footprint.
HYCM has also announced the introduction of a new logo to reflect these developments which will replace the existing one and will appear on the Group’s website as well as all its advertising and promotional materials from April 2017.
HYCM
Notes to editors:
HYCM is a leading provider of online FX and CFD trading services to retail and institutional investors. With a 40 year operational history and a strong focus on client satisfaction and technological advancement, HYCM has become the online broker of choice for investors across the globe, providing access to a range of asset classes including currencies, commodities, metals, shares and indices.
HYCM offers clients a complete trading solution together with all the trading tools and analysis needed to make informed trading decisions. Backed by its state-of-the-art trading platforms, including the industry leading MetaTrader 4 and mobile app enabling clients to trade while on the go, HYCM has secured a strong industry reputation for delivering a trading experience that is second to none.
HYCM is part of the Henyep Capital Markets Group, an international conglomerate with businesses in financial services, property, education and charity and is regulated by the Financial Conduct Authority of the UK (FCA reference number 186171 and the Cyprus Securities and Exchange Commission (CySEC licence number 259/14).
The company is represented globally with offices in United Kingdom, Hong Kong, Cyprus and Dubai.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170330005484/en/
Contact:
HYCM
Rosemary Barnes
Email: rosemary.barnes@hycm.com
Telephone:
+357 25 24 5750
www.hycm.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom